Radioiodine Remnant Ablation for Differentiated Thyroid Canc
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
This study suggests that low-activity radioactive iodine (RAI) is comparable with high-activity RAI regarding recurrence rates and thus should be considered because of its similar efficacy but lower morbidity.

The objective of this JAMA study was to evaluate the long-term cure rate of different RAI activities in low- and intermediate-risk differentiated thyroid cancer (DTC). Secondary outcomes included successful remnant ablation, adverse effects, and hospital length of stay.

A systematic search of the databases PubMed, Cochrane Collaboration, Embase, Scopus, and Web of Science was performed to identify randomized clinical trials (RCTs) and observational studies that compared long-term outcomes (>12 months) for American Thyroid Association–classified low- and intermediate-risk DTC based on receipt of either low-activity or high-activity RAI postoperatively.

Ten studies that included 3821 patients met inclusion criteria, including 6 RCTs and 4 observational studies. There was no difference in long-term cure recurrence rates or successful remnant ablation between low-activity and high-activity RAI.

In conclusion, low-activity RAI was comparable with high-activity RAI regarding successful ablation and recurrence rates. This suggests that low-activity RAI is preferable to high-activity in low- and intermediate-risk DTC because of its similar efficacy but reduced morbidity.

Source: https://jamanetwork.com/journals/jamaotolaryngology/article-abstract/2778214
Like
Comment
Share